STAT+: Aurinia in ‘show-me phase’ as FDA nears approval decision on autoimmune kidney disease drug
Next week, the Food and Drug Administration is expected to approve a new medicine from Aurinia Pharmaceuticals that will be used to treat patients with lupus nephritis, a serious autoimmune kidney disease.
If the decision goes Aurinia’s way, the oral drug called voclosporin will be the first commercial product developed successfully by the drug maker, founded in 1993 and based in Victoria, British Columbia, in Canada.
Continue to STAT+ to read the full story…
